secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-045896
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted
--------------------------------------------------------------------------------

- Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.
- Raised $188M net in April 2025 public offering; pro-forma cash exceeds $624M as of close.
- Q1 2025 net loss of $40.8M ($0.43 loss/share); R&D expense $36.8M, G&A stable at $9.2M.
- Sevasemten Phase 2 LYNX/FOX Duchenne data expected Q2 2025; Part D CIRRUS-HCM data due H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/0001104659-25-045896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer